A Study of BL-B01D1 and Almonertinib in Patients With Resectable EGFR+ Stage II-IIIB NSCLC

Abroad (travel likely)RecruitingPHASE2

Conditions

Non-Small Cell Lung Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

West China Hospital, Sichuan University, Chengdu, Sichuan, China
Contact: Study coordinator (Yue Chen) · cy9209@163.com · 8602885421606

Study leads

Yongsheng Wang
Principal Investigator
West China Hospital
Lunxu Liu
Principal Investigator
West China Hospital

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

Non-Small Cell Lung Cancer

Abroad (travel likely)RecruitingPHASE2

Orange, United States · Skokie, United States

Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)

High Grade Epithelial Ovarian Cancer · High Grade Serous Ovarian Cancer · Primary Peritoneal Carcinoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Phoenix, United States · Tucson, United States

Dual-Target CAR-NK Cells Targeting MSLN, EGFR, or HER2 in Advanced NSCLC

Non-Small Cell Lung Cancer · Advanced/Metastatic

Abroad (travel likely)RecruitingPHASE1, PHASE2

Shenzhen, China

Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC

Carcinoma · Non-Small-Cell Lung · Lung Cancer (NSCLC)

Abroad (travel likely)RecruitingPHASE2

Hinsdale, United States · New Lenox, United States